Market Sell-Off Is Not a Good Sign for M&A in 2019, UBS's Forbes Says

The transcript discusses the current state of the market, focusing on M&A trends, risks, and the role of private equity and strategic bids. It highlights the challenges faced by biotech startups and Big Pharma, including the impact of tax reforms and mergers. The influence of Amazon on the healthcare market is examined, along with regulatory challenges and the role of activist investors. The discussion also touches on Brexit and its implications for the market.

How does Brexit affect M&A activity in the UK according to the text?

What challenges do biotech startups face in the current market environment?

In what ways has Big Pharma changed its approach to acquisitions and R&D?